» Articles » PMID: 33423935

The Spinal Distribution of Metastatic Renal Cell Carcinoma: Support for Locoregional Rather Than Arterial Hematogenous Mode of Early Bony Dissemination

Overview
Journal Urol Oncol
Publisher Elsevier
Date 2021 Jan 11
PMID 33423935
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Quantifying the degree to which spinal involvement of metastatic renal cell carcinoma (mRCC) is a locoregional phenomenon vs. a hematogenous, bone-specific affinity has implications for prognosis and antimetastatic therapy.

Objective: To investigate the distribution of spinal metastasis in mRCC and to explore relationships between clinical factors and patterns of spinal spread.

Methods: Patients with mRCC and spinal involvement from June 2005 to November 2018 were identified. Clinical and biologic features including primary tumor size and degree of spinal and nonbony metastatic involvement were collected. Spinal distributions were evaluated by the permutation test, with the null hypothesis that metastases are distributed uniformly across levels.

Results: One hundred patients with 685 spinal levels involved by mRCC were evaluated. A nonuniform spatial distribution was observed across the cohort (P < 0.001); a preponderance of thoracolumbar involvement was noted with the mode at L3. No significant deviation in metastatic distribution from uniform was observed in right- or left-sided tumors, subgroups of distant or local metastases, or histology. Patients with smaller tumors (<4 cm) and local spread had distribution of spinal metastases not significantly different from uniform (P = 0.292 and P = 0.126, respectively).

Conclusions: These data support a dominant locoregional as opposed to arterial hematogenous mechanism for early spinal dissemination of mRCC. Characterizations of the biologic molecular features contributing to osseous tropism and aggressive tumor biology (as seen in the subset of outlier patients with small tumors who appear to have more uniform spread), have implications for surveillance and are an area of active investigation.

Citing Articles

Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy.

Fomchenko E, Bayley J, Alvarez-Breckenridge C, Rhines L, Tatsui C Neurospine. 2023; 19(4):978-993.

PMID: 36597635 PMC: 9816609. DOI: 10.14245/ns.2244290.145.

References
1.
Lerner S, Hawkins C, Blute M, Grabner A, Wollan P, Eickholt J . Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996; 155(6):1868-73. View

2.
Kato S, Murakami H, Demura S, Nambu K, Fujimaki Y, Yoshioka K . Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up. J Surg Oncol. 2016; 113(5):587-92. DOI: 10.1002/jso.24186. View

3.
Sathiakumar N, Delzell E, Morrisey M, Falkson C, Yong M, Chia V . Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat. 2011; 131(1):231-8. DOI: 10.1007/s10549-011-1721-x. View

4.
Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A . Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2010; 48(1):160-6. DOI: 10.1016/j.bone.2010.09.008. View

5.
Knudsen B, Gmyrek G, Inra J, Scherr D, Vaughan E, Nanus D . High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002; 60(6):1113-7. DOI: 10.1016/s0090-4295(02)01954-4. View